Showing results (461-470 of 794) with videos related to

Sort By:
Pageof 80
Haematologica|July 24, 2025
Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodiesMatthew J Rees, Surendra Dasari, Ellen D McPhail, et al.
Blood Cancer Journal|December 6, 2023
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myelomaAmit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, et al.
British Journal of Haematology|June 2, 2020
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemicEfstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 12, 2013
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratificationLuciano J Costa, Elizabeth J Nista, Francis K Buadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomicsLiewei Wang, Shaji Kumar, Brooke L Fridley, et al.
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Blood Cancer Journal|February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee ReportDavid L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
The Lancet. Oncology|December 3, 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
British Journal of Haematology|July 5, 2012
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phaseDisni Muringampurath-John, David L Jaye, Christopher R Flowers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Pageof 80